NCT06544720 SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
| NCT ID | NCT06544720 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | The Affiliated Hospital of Qingdao University |
| Condition | Human Papillomavirus Associated Carcinomas |
| Study Type | INTERVENTIONAL |
| Enrollment | 18 participants |
| Start Date | 2023-08-02 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 18 participants in total. It began in 2023-08-02 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Eligibility Criteria
Key Inclusion Criteria: 1. Greater than or equal to 18 years of age 2. HPV associated carcinomas 3. Patients must have at least one measurable lesion defined by RECIST 1.1 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Key Exclusion Criteria: 1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory. 2. Patients with active autoimmune diseases. 3. Patient has a known active Hepatitis B or Hepatitis C. 4. Other severe medical conditions that may limit subject\'s participation in this trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06544720 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Human Papillomavirus Associated Carcinomas. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06544720 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06544720 currently recruiting?
Yes, NCT06544720 is actively recruiting participants. Contact the research team at qdlhytiger@163.com for enrollment information.
Where is the NCT06544720 trial being conducted?
This trial is being conducted at Qingdao, China.
Who is sponsoring the NCT06544720 clinical trial?
NCT06544720 is sponsored by The Affiliated Hospital of Qingdao University. The trial plans to enroll 18 participants.